TABLE 1.

Genotyping and antibiogram of tested MRSA strains

CategoryaSourcebStrain nameCoagulase isotypeMIC (mg/liter) ofc:SCCmec typedPFGE patternMLSTluk-PVgDoubling time (min)hReference(s)
ERYKANTOBGENTETNOROXACZXIMPST, allelic profileeCCf
CMN, USC199800037070.580.50.532145120.25IVaJ41, 1-1-1-1-1-1-11+27.893, 24
CND, USC199900052970.540.50.250.518>5120.5IVaJ41, 1-1-1-1-1-1-11+26.383, 24
CMN, USC199900019370.580.50.50.514>5120.25IVaJ31, 1-1-1-1-1-1-11+26.733, 24
CND, USMW270.540.250.250.518>5120.5IVaJ41, 1-1-1-1-1-1-11+28.672, 3, 24
CMN, USC20010012017>51280.250.250.518>5120.5IVaJ41, 1-1-1-1-1-1-11+27.43, 24
CMN, USC200100010170.580.50.50.514>5120.25IVaJ41, 1-1-1-1-1-1-11+27.253, 24
CMN, USC2001008187>51280.50.250.5116>5120.25IVaJ51, 1-1-1-1-1-1-11+27.723, 24
CWoo, AUA80 335540.540.250.250.5216>5120.125IVaH130, 2-2-2-2-6-3-230+26.2225
CWoo, AUA82 354940.520.250.250.5216>5120.125IVaH330, 2-2-2-2-6-3-230+28.0925
CWoo, AUA83 052840.540.250.250.5216>512≤0.063IVaH130, 2-2-2-2-6-3-230+27.0825
CWoo, AUB82 655940.520.250.250.5216512≤0.063IVaH130, 2-2-2-2-6-3-230+27.5725
CWoo, AUD82 155240.520.250.250.5216>5120.125IVaH130, 2-2-2-2-6-3-230+61.0325
CWoo, AUE80 253740.540.250.250.528>512≤0.063IVaH230, 2-2-2-2-6-3-230+26.9725
CWoo, AUF81 053940.540.250.250.5216>512≤0.063IVaH130, 2-2-2-2-6-3-230+26.4425
CWoo, AU180 255240.520.250.250.52165120.125IVaH330, 2-2-2-2-6-3-230+26.8625
CPer, AUiM9N3>51240.250.250.52165120.125IVaI178, 22-1-14-23-12-53-3129826.7526
CPer, AUiM33T3>51240.250.250.52165120.125IVaI278, 22-1-14-23-12-53-3129826.4426
CPer, AUiW1S10.520.50.250.50.52320.063NewE245, 10-14-8-6-10-3-24527.7426
CPer, AUiC7N7>51240.50.50.52165120.25IVaJ61, 1-1-1-1-1-1-1130.2626
CTN, USj0021570.2540.50.250.50.564>5122IVaE145, 10-14-8-6-10-3-24527.7128
CMS, USk01083364>5120.50.5321685120.125IVaA38, 3-3-1-1-4-4-38+27.784
CMS, USk010935165120.50.50.5216>5120.125IVaF72, 1-4-1-8-4-4-3825.944
CMS, USk0110230.2540.50.50.518>5120.25IVbA28, 3-3-1-1-4-4-38+28.294
NAde, AU81 034230.2540.50.50.58216≤0.063NewA18, 3-3-1-1-4-4-3826.86This study
NAde, AU91 257270.540.250.250.514>5120.25IVaJ71, 1-1-1-1-1-1-1127.15This study
NAde, AU91 261970.580.50.50.5264>5122IVaJ776, 1-63-1-1-1-1-1127.47This study
NAde, AUWCH37970.520.250.50.5116>5124IVaJ81, 1-1-1-1-1-1-1133.31This study
NAde, AU91 257470.2510.250.250.51288256≤0.063NewG22, 7-6-1-5-8-8-62229.52This study
NAde, AUSAP2602>51240.50.250.50.54>5120.25IVaB73, 1-4-27-4-12-1-10526.64This study
NPer, AU81 093770.520.250.50.514>5120.5IVaJ11, 1-1-1-1-1-1-1125.29This study
NPer, AU91 212570.540.250.50.50.516>5120.5IVaJ21, 1-1-1-1-1-1-1130.25This study
NPer, AU91 170330.2520.1250.2581165120.125IVaA28, 3-3-1-1-4-4-3832.0This study
NBri, AU81 123870.520.250.50.518>5120.5IVaJ11, 1-1-1-1-1-1-1126.06This study
NBri, AU91 266670.520.50.250.50.525120.125IVaJ21, 1-1-1-1-1-1-1126.65This study
NDar, AUSAP4116≤0.12540.250.532141280.125IVaN75, 36-3-43-34-39-52-49S27.68This study
HAde, AU81 05084>5122562560.50.25512512>512128IIM236, 2-2-2-2-3-3-23032.22This study
HAde, AU91 22314>51220.250.53232128>51216IIIK4239, 2-3-1-1-4-4-3835.8This study
HBri, AU91 15734>51212864816164>5124IIIK2239, 2-3-1-1-4-4-3841.82This study
HBri, AU91 15754>5125121632132256>51232IIIK6239, 2-3-1-1-4-4-3850.46This study
HBri, AU91 21454>5125121632323264>51216IIIK1239, 2-3-1-1-4-4-3850.64This study
HDar, AUSAP3444>51240.250.53232256>51232IIIK3239, 2-3-1-1-4-4-3834.51This study
HPer, AU91 21184>512512163232256512>51264IIIL239, 2-3-1-1-4-4-3838.45This study
HUKNCTC1044230.12510.1250.51281256>51216ID250, 3-3-1-1-4-4-16836.4419
HJPN3152>512>5125120.50.125216161IIC5, 1-4-1-4-12-1-10534.2819
HNZ85/20824512>512864128232>5120.5IIIK5239, 2-3-1-1-4-4-3843.5319
HUKStrain 252l4>5121281280.250.5>512512>51264IIM136, 2-2-2-2-3-3-23029.7920, —m
HUKMSSA47670.540.50.5110.58≤0.063J11, 1-1-1-1-1-1-1127.66m
  • a C, C-MRSA; N, NORSA; H, H-MRSA.

  • b MN, Minnesota; US, United States; ND, North Dakota; Woo, Wooloongabba, Australia, AU, Australia; Per, Perth, Australia; TN, Tennessee; MS, Mississippi; Ade, Adelaide, Australia; Bri, Brisbane, Australia; Dar, Darwin, Australia; UK, United Kingdom; JP, Japan; NZ, New Zealand.

  • c MICs were determined by the NCCLS-based plate dilution method. Antibiotics: ERY, erythromycin; KAN, kanamycin; TOB, tobramycin; GEN, gentamicin; TET, tetracycline; NOR, norfloxacin; OXA, oxacillin; CZX, ceftizoxime; IMP, imipenem. Values in bold signify resistance to these antibiotics.

  • d New, new type of SCCmec possessing class C2 mec gene complex (see Fig. 2).

  • e ST, sequence type.

  • f Clonal complex, based on BURST (based upon related sequence types). S, singleton (not assigned to any clonal complex).

  • g luk-PV genes encode Panton-Valentin leucocidin proteins.

  • h Doubling time during exponential growth phase (optical density of 0.05 to ∼1.0 at 660 nm) measured by using TN-2612 (Advantec Toyo Kaisha, Ltd., Tokyo, Japan) as previously described (8).

  • i Isolated from aborigine.

  • j Isolated from food-poisoning strain.

  • k Isolated from state prison.

  • l E-MRSA16.

  • m —, http://www.sanger.ac.uk/Projects/S.aureus/.